Caidya Executive and Leadership Team

Barbara Kunz, the Chief Executive Officer at Caidya, directs the overarching strategic vision and operational growth of the organization. Kunz architects the long-term roadmap for multi-therapeutic clinical research services, ensuring alignment with the evolving needs of global innovators. By fostering a culture of delivery excellence, the Chief Executive Officer drives the integration of proprietary clinical technology across all trial phases. Barbara Kunz maintains direct oversight of executive leadership initiatives, ensuring that every clinical development program meets rigorous quality standards. This leadership role involves constant engagement with the Board to secure sustainable market expansion and operational efficiency. Through the implementation of data-driven decision-making frameworks, the Chief Executive Officer optimizes trial transparency and accelerates submission timelines. Ultimately, Kunz secures the competitive position of the firm within the complex landscape of global clinical research organizations.

Holly Guile, the Chief of Staff & Chief Executive Officer, Office at Caidya, manages the internal operational cadence and strategic execution of the executive office. Guile coordinates cross-functional workflows to ensure that organizational objectives remain synchronized with the broader mission of delivering superior clinical research services. Holly Guile facilitates communication between the C-suite and departmental leads, streamlining decision-making processes to enhance overall productivity. By overseeing the administrative infrastructure, the Chief of Staff & Chief Executive Officer, Office enables the seamless delivery of clinical services from pre-IND strategy to post-marketing surveillance. This role involves managing high-priority projects that impact the firm's operational scale across international markets. Through meticulous planning and resource allocation, the Chief of Staff & Chief Executive Officer, Office supports the firm's commitment to an elevated customer experience, ensuring that internal operations consistently reflect the high standards required for complex clinical development.

Sharon Moore, the Chief Medical Officer at Caidya, provides clinical leadership and scientific oversight for all multi-therapeutic research programs. Moore directs the medical strategy, ensuring that trial designs adhere to global regulatory standards and scientific best practices. Sharon Moore evaluates clinical data to support informed decision-making, enhancing the quality of submissions and post-marketing surveillance efforts. By collaborating with internal research teams and external partners, the Chief Medical Officer ensures that therapeutic expertise remains at the forefront of every clinical development project. This role involves navigating complex medical challenges to maintain trial integrity and patient safety across diverse geographic operations. Through the application of advanced clinical knowledge, the Chief Medical Officer drives the success of complex trials, ultimately facilitating the transition of innovative therapies from development to market. Moore maintains a focus on scientific rigor to uphold the reputation of the organization as a leader in clinical research.

David Rifkind, the Chief Legal Officer at Caidya, manages the legal framework and regulatory compliance requirements for the entire organization. Rifkind architects the risk management strategies necessary to protect the firm during complex clinical development and submission processes. David Rifkind oversees all contractual obligations with global partners, ensuring that legal standards align with the company's commitment to trial transparency and data integrity. By providing counsel on intellectual property and regulatory matters, the Chief Legal Officer supports the firm's expansion into new therapeutic areas and international markets. This leadership role involves close collaboration with the executive team to navigate the legal complexities of post-marketing surveillance and clinical research operations. Through proactive legal oversight, the Chief Legal Officer mitigates potential liabilities and ensures that all business activities remain compliant with global health regulations. Rifkind secures the long-term stability of the organization by maintaining a robust legal foundation.